Gel dressing for relieving postoperative lymphedema of breast cancer and preparation method of gel dressing
The gel dressing prepared by modifying biomaterials solves the problems of unstable adhesion and uncontrollable drug release in the treatment of lymphedema after breast cancer surgery. It achieves controlled sustained release and enhanced penetration of drugs, improves the therapeutic effect, and is suitable for the nursing care of lymphedema after breast cancer surgery.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- PINGYANG COUNTY PEOPLES HOSPITAL
- Filing Date
- 2026-03-11
- Publication Date
- 2026-05-05
AI Technical Summary
Existing hydrogel dressings have unstable adhesion in the treatment of lymphedema after breast cancer surgery, uncontrollable drug release, and difficulty in achieving continuous and gentle drug delivery. Furthermore, lipid-soluble drugs have low transdermal efficiency, resulting in poor treatment outcomes.
A gel dressing was prepared using modified biomaterials. Mussel adhesive protein and menthol were covalently linked to form a stable gel network, which sustained-released the active ingredients and improved the transdermal efficiency of lipid-soluble drugs. Combined with the anti-inflammatory, antipruritic, and antibacterial properties of mussel adhesive protein, the drug was delivered in a controlled manner.
In the treatment of lymphedema after breast cancer surgery, gel dressings can maintain stable adhesion in complex usage scenarios, achieving sustained drug release and enhanced penetration, improving treatment efficacy, reducing secondary skin damage, and providing continuous local drug delivery and anti-inflammatory effects.
Smart Images
Figure CN121971689A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medical dressing technology, specifically relating to a gel dressing for relieving postoperative lymphedema in breast cancer patients and its preparation method. Background Technology
[0002] Post-mastectomy lymphedema is often associated with factors such as obstructed axillary lymphatic drainage, radiotherapy-induced fibrosis, and local chronic inflammation. Clinically, it manifests as swelling, tightness, heaviness, dryness, and itching in areas such as the affected upper limb, the anterior axillary fold, and the inner upper arm. Prolonged pressure from elastic sleeves / bandages can exacerbate friction irritation, maceration dermatitis, and micro-cracks. Damage to the skin barrier increases the risk of bacterial colonization or cellulitis, which can further cause fluctuations or even worsen swelling, creating a vicious cycle of skin damage-infection / inflammation-edema. Therefore, skin dressings for patients with lymphedema need to be comfortable, breathable, and biocompatible, while also ensuring stable adhesion on wet surfaces and regulating the local microenvironment.
[0003] Existing hydrogel dressings are mostly based on hyaluronic acid, alginate, or a single hydrophilic polymer, primarily providing moisturizing or simple drug-carrying functions. Traditional dressings have insufficient adhesion and retention under sweat and activity conditions, making them prone to falling off and shifting. Drug release is rapid but uncontrollable, making it difficult to achieve continuous, gentle, and controlled delivery in edematous skin environments. Traditional dressings also have limited loading and transdermal delivery efficiency for lipid-soluble drugs, resulting in insufficient local effective drug throughput. Especially for problems related to lymphedema such as tissue fluid retention, chronic inflammation, and fragile skin barriers, comprehensive therapeutic effects are difficult to achieve. Summary of the Invention
[0004] In response to the above situation, the present invention provides a gel dressing for relieving postoperative lymphedema of breast cancer and its preparation method. Based on modified biomaterials, the dressing achieves gelling properties, giving it sustained release, adhesion and sufficient mechanical strength. As the gel network deconstructs, covalent bonds break, releasing active ingredients that promote penetration and reduce swelling, while improving the skin penetration efficiency of lipid-soluble drugs, thereby achieving the purpose of lymphedema care and treatment.
[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows: This invention provides a gel dressing for relieving postoperative lymphedema in breast cancer patients. The gel dressing comprises the following raw materials in parts by weight: 0.1-0.5 parts of active pharmaceutical ingredient, 8-12 parts of modified matrix, 0.2-0.8 parts of dopamine hydrochloride, 2 parts of dispersant, and 0.5-1.5 parts of enhancer.
[0006] Furthermore, the active pharmaceutical ingredient is selected from any one of ketoprofen, doxycycline, and VEGF-C (vascular endothelial growth factor C).
[0007] Furthermore, the dispersant is selected from any one of β-cyclodextrin, Tween 80, and BSA (bovine serum albumin).
[0008] Furthermore, the reinforcing agent is selected from any one of gelatin, nanocellulose, and chitosan.
[0009] Furthermore, the modified matrix comprises the following raw materials: mussel adhesive protein, menthol, succinic anhydride, NHS (N-hydroxysuccinimide), EDC (1-ethyl-(3-dimethylaminopropyl)carbodiimide), and 2-iminothione, wherein the mass ratio of mussel adhesive protein, menthol, menthol, NHS, EDC, and 2-iminothione is 80:8:6:5:8:6.
[0010] Furthermore, the modified matrix is prepared as follows: S1: Dissolve menthol and add succinic anhydride to it and stir to react. The hydroxyl groups in menthol undergo a nucleophilic reaction with succinic anhydride, and the anhydride opens the ring to form a half-ester structure. One end is used to covalently connect with menthol, and the other end retains the carboxyl group, which provides a reaction site for subsequent coupling with mussel adhesive protein. After the reaction is completed, rotary evaporate to obtain modified menthol. S2: Modified menthol, NHS and EDC are dissolved and reacted together. EDC activates the carboxyl group retained at one end after the ring opening of succinic anhydride in modified menthol to generate an O-acyl isourea intermediate. After being replaced by NHS, a more stable and more reactive NHS active ester is generated, thus obtaining esterified menthol. S3: Dissolve mussel adhesive protein to obtain a protein solution. While stirring, add esterified menthol to the protein solution to carry out the reaction and covalent linkage. The lysine residues or N-terminal amino groups in the mussel adhesive protein undergo affinity substitution for the NHS ester in the esterified menthol to form a stable amide bond. After the reaction is completed, dialysis purification is performed to obtain the modified protein. S4: Add 2-iminothione to the modified protein. The reaction introduces thiol groups, which facilitates the cross-linking of the protein into a gel under mild conditions. After purification and drying, the modified matrix is obtained.
[0011] This invention also provides a method for preparing a gel dressing to relieve lymphedema after breast cancer surgery, the specific steps of which are as follows: Step 1: Dissolve the active drug and dispersant separately to obtain a drug solution and a dispersion. Slowly add the drug solution dropwise to the dispersion for drug encapsulation, dispersion and stabilization to obtain a pretreated drug solution. Dissolve the modified matrix and enhancer together to obtain a matrix solution. Step 2: Mix the pretreatment drug solution and the matrix solution evenly to obtain the drug-loaded gel solution. Dissolve dopamine hydrochloride and mix it with the drug-loaded gel solution under heating conditions to remove bubbles and obtain a gel-like gel. Step 3: Place the gel in a mold, cool and solidify it, and sterilize it to obtain a gel dressing for relieving lymphedema after breast cancer surgery.
[0012] The beneficial effects achieved by this invention are as follows: This invention presents a gel dressing for relieving post-operative lymphedema in breast cancer patients. Addressing the issues of impaired local microcirculation and lymphatic drainage leading to chronic inflammation and tissue remodeling in the long-term management of post-operative lymphedema, as well as the vulnerability of the skin barrier, insufficient transdermal drug throughput, and unstable drug release under compression therapy, this invention proposes a biocompatible functional dressing based on modified biological protein as the gel matrix material. By first introducing menthol into a couplerable hemiester structure and then covalently grafting it onto mussel adhesive protein, the permeation-enhancing unit not only possesses sustained-release, permeation-enhancing, and anti-swelling effects but also promotes the stability of the gel cross-linking network. The introduced thiol groups endow the gel matrix with the potential for cross-linking and gelation under mild conditions. Mussel adhesive protein serves as both a drug-loaded gel matrix material and possesses anti-inflammatory, antipruritic, antioxidant, melanin-inhibiting, and antibacterial adhesive activities. Menthol, as an active permeation-enhancing unit, remains molecularly stable within the gel material, maintaining enhanced stratum corneum permeability for a prolonged period after application, thus improving the transdermal penetration efficiency of lipid-soluble active drugs. Furthermore, it reduces displacement and secondary skin damage caused by frequent changes in complex application scenarios such as sweat and skin stretching. In the highly inflammatory, high-tissue-fluid, and high-enzyme microenvironment of lymphedema, the covalent bond between menthol and mussel adhesive protein undergoes slow hydrolysis and breakage. This results in slow gel collapse for sustained drug release, while the released menthol continuously acts on the skin, promoting permeation and vasodilation. Menthol also exhibits diuretic and anti-edema effects, playing different roles at different stages of lymphedema after breast cancer surgery. The released free menthol synergistically enhances therapeutic efficacy with the active drug, providing a more stable, controllable, and efficient local drug delivery in the actual care or treatment of lymphedema after breast cancer surgery, demonstrating promising application prospects. Attached Figure Description
[0013] Figure 1 The fluid state of the gel dressing for relieving post-mastectomy lymphedema prepared in Example 4 before and after molding; Figure 2 Scanning electron microscope image of the gel dressing for relieving postoperative lymphedema of breast cancer prepared in Example 4; Figure 3 The results of the cell compatibility study of the gel dressings prepared in Examples 1-4 and Comparative Examples 1-2; Figure 4 The results of the transdermal permeability study of the gel dressings prepared in Example 4 and Comparative Examples 1-2; Figure 5The results show the change rate of tail volume in mice with lymphedema in the blank group, control group, and Example 4 group. Detailed Implementation
[0014] The technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.
[0015] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those familiar to those skilled in the art. Furthermore, any methods and materials similar to or equivalent to those described herein may be applied to this invention. The preferred embodiments and materials described herein are for illustrative purposes only and do not limit the scope of this application.
[0016] Unless otherwise specified, all methods used in the following examples are conventional. All parts of the materials used in the following examples are by weight. Unless otherwise specified, all raw materials are new materials purchased from the market. Specifically, the mussel adhesive protein used is a commercially available freeze-dried powder product with a molecular weight of 16.06 kDa, an isoelectric point of 10.01, a protein content ≥95%, and a water solubility of 5.9 mg / mL. The menthol used is L-menthol, a crystalline solid. The ketoprofen, doxycycline, and VEGF-C used are all pharmaceutical-grade raw materials. The dopamine hydrochloride used is water-soluble dopamine hydrochloride. The chitosan used is of medium viscosity, 200-400 mPa·s.
[0017] In the following examples and comparative examples, the modified matrix used includes the following raw materials in parts by weight: 80 parts mussel adhesive protein, 8 parts menthol, 6 parts succinic anhydride, 5 parts NHS, 8 parts EDC and 6 parts 2-iminothione. The modified matrix is prepared as follows: S1: Dissolve 8 parts of menthol in 1.5 mL of anhydrous ethanol, then add 6 parts of succinic anhydride and stir at 200 rpm for 2 h. After the reaction is complete, remove the solvent by rotary evaporation to obtain modified menthol. S2: Modified menthol, 5 parts of NHS and 8 parts of EDC were dissolved together in 2 mL of DMF (N,N-dimethylformamide) and stirred at 200 rpm for 30 min to obtain esterified menthol; S3: Dissolve 80 portions of mussel adhesive protein in 10 mL of 0.1 M carbonate buffer to obtain a protein solution. While stirring at 350 rpm, add esterified menthol dropwise to the protein solution. After the addition is complete, continue the reaction for 3 h to perform covalent linkage. After the reaction is complete, dialysis is performed to purify the protein. The molecular weight cutoff of the dialysis bag is 10 kDa. The dialysis medium is deionized water, and the dialysis time is 12 h to obtain the modified protein. S4: Add 6 parts of 2-iminothione to the modified protein, react for 45 min to introduce thiol groups, continue to dialyze for purification, freeze dry to obtain the modified matrix.
[0018] Example 1: This example provides a gel dressing for relieving lymphedema after breast cancer surgery. The gel dressing includes the following raw materials in parts by weight: 0.2 parts ketoprofen, 10 parts modified matrix, 0.4 parts dopamine hydrochloride, 2 parts β-cyclodextrin and 0.8 parts nanocellulose.
[0019] This embodiment also provides a method for preparing a gel dressing to relieve lymphedema after breast cancer surgery, the specific steps of which are as follows: Step 1: Dissolve 0.2 parts of ketoprofen and 2 parts of β-cyclodextrin in 2 mL of anhydrous ethanol and 10 mL of PBS (pH 7.4 phosphate buffer), respectively, to obtain a drug solution and a dispersion. Slowly add the drug solution to the dispersion at 45℃ and 600 rpm with stirring. After the addition is complete, continue stirring for 30 min to obtain a pretreated drug solution. Dissolve 10 parts of the modified matrix and 0.8 parts of nanocellulose in 35 mL of PBS. Let it stand at 4℃ for 10 min to hydrate and then stir at 300 rpm for 20 min to swell, to obtain the matrix solution. Step 2: Mix the pretreated drug solution and matrix solution evenly to obtain the drug-loaded gel solution. Dissolve 0.4 parts of dopamine hydrochloride in 5 mL of PBS and mix it with the drug-loaded gel solution at 50°C. Degas under vacuum for 3 min to obtain a gel-like gel. Step 3: Place the gel in a mold, cool and solidify it, and sterilize it with ultraviolet light to obtain a gel dressing for relieving lymphedema after breast cancer surgery.
[0020] Example 2: This example provides a gel dressing for relieving lymphedema after breast cancer surgery. The gel dressing includes the following raw materials in parts by weight: 0.1 parts doxycycline, 12 parts modified matrix, 0.2 parts dopamine hydrochloride, 2 parts Tween 80 and 1.5 parts gelatin.
[0021] This embodiment also provides a method for preparing a gel dressing to relieve lymphedema after breast cancer surgery, the specific steps of which are as follows: Step 1: Dissolve 0.1 parts of doxycycline and 2 parts of Tween 80 in 2 mL of anhydrous ethanol and 10 mL of PBS respectively to obtain a drug solution and a dispersion. Slowly add the drug solution to the dispersion while stirring at 45℃ and 600 rpm. After the addition is complete, continue stirring for 30 min to obtain a pretreated drug solution. Dissolve 12 parts of the modified matrix and 1.5 parts of gelatin together in 35 mL of PBS. Let it stand at 4℃ for 10 min to hydrate and then stir at 300 rpm for 20 min to swell to obtain a matrix solution. Step 2: Mix the pretreated drug solution and matrix solution evenly to obtain the drug-loaded gel solution. Dissolve 0.2 parts of dopamine hydrochloride in 5 mL of PBS and mix it with the drug-loaded gel solution at 50°C. Degas under vacuum for 3 min to obtain a gel-like gel. Step 3: Place the gel in a mold, cool and solidify it, and sterilize it with ultraviolet light to obtain a gel dressing for relieving lymphedema after breast cancer surgery.
[0022] Example 3: This example provides a gel dressing for relieving lymphedema after breast cancer surgery. The gel dressing includes the following raw materials in parts by weight: 0.5 parts VEGF-C, 8 parts modified matrix, 0.8 parts dopamine hydrochloride, 2 parts BSA and 0.5 parts chitosan.
[0023] This embodiment also provides a method for preparing a gel dressing to relieve lymphedema after breast cancer surgery, the specific steps of which are as follows: Step 1: Dissolve 0.5 parts of VEGF-C and 2 parts of BSA in 2 mL of deionized water and 10 mL of PBS respectively to obtain a drug solution and a dispersion. Slowly add the drug solution to the dispersion while stirring at 45℃ and 600 rpm. After the addition is complete, continue stirring for 30 min to obtain a pretreated drug solution. Dissolve 8 parts of the modified matrix and 0.5 parts of chitosan in 33 mL of PBS. Let it stand at 4℃ for 10 min to hydrate and then stir at 300 rpm for 20 min to swell to obtain a matrix solution. Step 2: Mix the pretreated drug solution and matrix solution evenly to obtain the drug-loaded gel solution. Dissolve 0.8 parts of dopamine hydrochloride in 5 mL of PBS and mix it with the drug-loaded gel solution at 50°C. Degas under vacuum for 3 min to obtain a gel-like gel. Step 3: Place the gel in a mold, cool and solidify it, and sterilize it with ultraviolet light to obtain a gel dressing for relieving lymphedema after breast cancer surgery.
[0024] Example 4: This example provides a gel dressing for relieving postoperative lymphedema in breast cancer patients. The gel dressing comprises the following raw materials in parts by weight: 0.4 parts VEGF-C, 10 parts modified matrix, 0.5 parts dopamine hydrochloride, 2 parts BSA and 0.8 parts chitosan.
[0025] This embodiment also provides a method for preparing a gel dressing to relieve lymphedema after breast cancer surgery, the specific steps of which are as follows: Step 1: Dissolve 0.4 parts of VEGF-C and 2 parts of BSA in 2 mL of deionized water and 10 mL of PBS respectively to obtain a drug solution and a dispersion. Slowly add the drug solution to the dispersion while stirring at 45℃ and 600 rpm. After the addition is complete, continue stirring for 30 min to obtain a pretreated drug solution. Dissolve 10 parts of the modified matrix and 0.8 parts of chitosan together in 33 mL of PBS. Let it stand at 4℃ for 10 min to hydrate and then stir at 300 rpm for 20 min to swell to obtain a matrix solution. Step 2: Mix the pretreated drug solution and matrix solution evenly to obtain the drug-loaded gel solution. Dissolve 0.5 parts of dopamine hydrochloride in 5 mL of PBS and mix it with the drug-loaded gel solution at 50°C. Degas under vacuum for 3 min to obtain a gel-like gel. Step 3: Place the gel in a mold, cool and solidify it, and sterilize it with ultraviolet light to obtain a gel dressing for relieving lymphedema after breast cancer surgery.
[0026] Comparative Example 1: The difference from Example 4 is that the mussel adhesive protein was not modified to prepare the modified matrix. Menthol and mussel adhesive protein were physically mixed and used to prepare the gel dressing. The rest of the process was the same as in Example 4.
[0027] Comparative Example 2: The difference from Example 4 is that BSA was not added to protect the VEGF-C drug; the rest is the same as Example 4.
[0028] Gel-forming performance evaluation: The gel dressing prepared in Example 4 was used, and its fluid state before and after molding was recorded. The results are shown in the table below. Figure 1 .
[0029] Microscopic morphology examination: The gel dressing prepared in Example 4 was examined by SEM (scanning electron microscopy), and its microscopic morphology was recorded. The results are shown in the figure. Figure 2 .
[0030] Cell compatibility assessment: 0.2 g of the gel dressings prepared in Examples 1-4 and Comparative Examples 1-2 were placed at the bottom of a 96-well plate and co-cultured with C166 (mouse vascular endothelial cells) for 24 h to assess the cell compatibility of the gel dressings. Wells with normally cultured cells served as the control group, and wells without added cells served as the blank group. Cell viability was detected using the CCK-8 assay. Cell viability (%) = (experimental group absorbance - control group absorbance) / (control group absorbance - blank group absorbance) × 100%. Results are shown in […]. Figure 3 .
[0031] Transdermal permeability assessment: The transdermal permeability of the gel dressings prepared in Example 4 and Comparative Examples 1-2 was assessed using a Franz diffusion cell. The effective diffusion area was 1.77 cm². 2 Degreased porcine skin with a recipient chamber volume of 12 mL and a thickness of 1 mm was sampled at 0, 0.5, 1, 4, 12, 24, and 48 h. Using the amount of drug in an equal mass of gel dressing as the total amount, the drug transdermal rate (%) at each time point was calculated as: (Material mass of drug in the recipient chamber of the diffusion cell / Total drug amount) × 100%. The results are shown in […]. Figure 4 .
[0032] Evaluation of Lymphedema Relief Effect: Establishment of a Small Number of Lymphedema Tail Ring Resection Model: Twelve 8-week-old female C57BL / 6 mice weighing 18-20g were randomly divided into a blank group, a control group, and the Example 4 group. A 3 mm ring resection was performed on the superficial and deep collecting lymphatic vessels of the tail at a distance of 0.5 cm from the tail root, avoiding damage to blood vessels. Drug administration began after model establishment in the second week. The blank group consisted of mice that had not undergone model establishment, the control group consisted of mice that did not receive drug treatment after model establishment, and the Example 4 group consisted of mice treated with the gel dressing prepared in Example 4 after model establishment. The tail volume of the mice was recorded at day 0 (beginning of model establishment), day 7 (end of model establishment), day 14 (successful model establishment), and days 18, 22, 26, 30, and 34 after successful model establishment. The volume change rate (%) was calculated as: tail volume at each time point / initial tail volume × 100%. Results are shown in […]. Figure 5 .
[0033] Figure 1 The results showed that the gel dressing prepared in Example 4 had a certain fluidity before molding and could be used in different molds. After curing, it had good adhesion and shape and was suitable for irregular skin conditions.
[0034] Figure 2 The results showed that the gel dressing prepared in Example 4 had a porous structure and a relatively rich and dense cross-linked network, which was beneficial to drug loading and stability.
[0035] Figure 3 The results showed that the gel dressings prepared in Examples 1-4 and Comparative Examples 1-2 all had good cell compatibility, demonstrating great application potential and high biosafety.
[0036] Figure 4The results showed that in Comparative Example 1, the gel dressing without menthol grafting released the drug relatively quickly, and the drug was basically completely released after 12 hours. This burst release behavior is not conducive to efficient absorption and utilization by the skin and recovery of lymphedema. In Comparative Example 2, the drug was not stabilized by BSA coating, and its final transdermal rate was low, with a large loss of drug activity and low utilization. The gel dressing prepared in Example 4 showed a sustained-release characteristic, and the transdermal rate of the drug at 48 hours still showed an increasing trend, which is beneficial for long-term treatment of lymphedema.
[0037] Figure 5 The results showed that the tail volume of the lymphedema model mice treated with the drug in Example 4 recovered well. On day 20 after drug administration (i.e. day 34 after modeling), the tail volume of the mice was close to the initial state volume, demonstrating a good therapeutic effect on lymphedema.
[0038] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.
[0039] The present invention and its embodiments have been described above. This description is not restrictive, and the accompanying drawings are only one embodiment of the present invention. The actual application is not limited to this. In conclusion, if those skilled in the art are inspired by this description and design similar methods and embodiments without departing from the spirit of the present invention, they should all fall within the protection scope of the present invention.
Claims
1. A gel dressing for relieving lymphedema after breast cancer surgery, characterized in that, The gel dressing comprises the following raw materials in parts by weight: 0.1-0.5 parts of active pharmaceutical ingredient, 8-12 parts of modified matrix, 0.2-0.8 parts of dopamine hydrochloride, 2 parts of dispersant, and 0.5-1.5 parts of reinforcing agent; The modified matrix comprises the following raw materials: mussel adhesive protein, menthol, succinic anhydride, NHS, EDC, and 2-iminothione. The preparation method of the modified matrix is as follows: S1: Dissolve menthol, add succinic anhydride to react, and then rotary evaporate to obtain modified menthol; S2: Modified menthol, NHS and EDC are dissolved and reacted together to obtain esterified menthol; S3: Dissolve mussel adhesive protein to obtain a protein solution, add esterified menthol to the protein solution for reaction and purification to obtain modified protein; S4: Add 2-iminothione to the modified protein. After the reaction is complete, purify and dry to obtain the modified matrix.
2. The gel dressing for relieving postoperative lymphedema in breast cancer patients according to claim 1, characterized in that, The mass ratio of mussel adhesive protein, menthol, menthol, NHS, EDC and 2-iminothione is 80:8:6:5:8:
6.
3. The gel dressing for relieving postoperative lymphedema in breast cancer patients according to claim 1, characterized in that, The active pharmaceutical ingredient is selected from any one of ketoprofen, doxycycline, and VEGF-C.
4. The gel dressing for relieving postoperative lymphedema in breast cancer patients according to claim 3, characterized in that, The dispersant is selected from any one of β-cyclodextrin, Tween 80, and BSA.
5. The gel dressing for relieving postoperative lymphedema of breast cancer patients according to claim 3, characterized in that, The reinforcing agent is selected from any one of gelatin, nanocellulose, and chitosan.
6. A method for preparing a gel dressing for relieving postoperative lymphedema of breast cancer patients according to any one of claims 1-5, characterized in that, The specific steps are as follows: Step 1: Dissolve the active drug and dispersant separately to obtain a drug solution and a dispersion. Add the drug solution dropwise to the dispersion to obtain a pretreated drug solution. Dissolve the modified matrix and reinforcing agent together to obtain a matrix solution. Step 2: Mix the pretreatment drug solution and the matrix solution to obtain the drug-loaded gel solution. Dissolve dopamine hydrochloride and mix it with the drug-loaded gel solution under heating conditions to remove bubbles and obtain a gel-like gel. Step 3: Place the gel in a mold, cool and solidify it, and sterilize it to obtain a gel dressing for relieving lymphedema after breast cancer surgery.